GlassScriptPhysician profile
Jasjit S Kochar
NPI 1043255250
$19,529.57
in general payments reported to CMS, 2019-2025
42 companies · $2,470 in 2025
The $2,470 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,239 · 2020: $2,125 · 2021: $1,582 · 2022: $3,152 · 2023: $3,215 · 2024: $3,746 · 2025: $2,470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,431.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,431.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,110.71 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $2,939.97 | 2019-2025 | Ozempic |
| Lilly USA, LLC | $1,789.97 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $1,570.70 | 2019-2025 | |
| Abbvie INC. | $1,420.77 | 2020-2025 | |
| Amgen INC. | $1,323.51 | 2019-2025 | Otezla, Repatha, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,220.08 | 2019-2025 | Jardiance, Ofev, Tradjenta |
| Sanofi-Aventis U.S. LLC | $703.65 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $701.81 | 2019-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $667.66 | 2021-2024 | |
| Amarin Pharma, INC. | $535.48 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $478.24 | 2019-2024 | Verquvo, Steglatro |
| Regeneron Healthcare Solutions, INC. | $440.81 | 2024-2025 | Dupixent |
| Abbott Laboratories | $424.57 | 2019-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Allergan, INC. | $250.98 | 2019-2020 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $241.16 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $226.37 | 2020-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $185.27 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $180.32 | 2024 | Voquezna |
| Sumitomo Pharma America, INC. | $174.00 | 2024-2025 | Gemtesa, Myfembree |
| Exact Sciences Corporation | $154.99 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $115.83 | 2023-2025 | Veozah, Myrbetriq |
| Kowa Pharmaceuticals America, INC. | $100.35 | 2022-2025 | Livalo, Zoryve, Seglentis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.68 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $59.88 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $54.63 | 2023-2024 | Quviviq |
| Genzyme Corporation | $41.53 | 2024 | |
| Corcept Therapeutics | $37.22 | 2025 | Korlym |
| Dexcom, INC. | $36.98 | 2022-2024 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $34.78 | 2019-2020 | |
| Medela LLC | $29.35 | 2021 | |
| Gynesonics, INC. | $28.19 | 2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Agios Pharmaceuticals, INC. | $23.16 | 2025 | Pyrukynd |
| Philips North America LLC | $23.11 | 2024 | (Ck7) Extended Holter |
| Exeltis, USA INC. | $20.61 | 2021 | |
| Medtronic, INC. | $19.53 | 2021 | |
| Dynavax Technologies Corporation | $18.82 | 2022 | |
| Medtronic Minimed, INC. | $18.35 | 2020 | |
| Phadia US INC. | $17.40 | 2025 | Immunocap |
| Seqirus USA INC | $16.76 | 2022 | |
| Rgh Enterprises LLC | $15.02 | 2025 | |
| Esperion Therapeutics, INC. | $14.37 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jasjit Kochar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.